Literature DB >> 7435569

Metabolism in man of 7-ketolithocholic acid: precursor of cheno- and ursodeoxycholic acids.

H Fromm, G L Carlson, A F Hofmann, S Farivar, P Amin.   

Abstract

To define the metabolism of 7-ketolithocholic acid in man, studies were carried out in gallstone patients with normal liver function. 7-[24-14C]ketolithocholic acid or its glycine or taurine conjugates were injected intravenously, and the chemical form of radioactivity appearing in bile was determined to define hepatic biotransformation. To study intestinal absorption 7-[24-14C]ketolithocholic acid was infused into the jejunum and ileum, respectively, and the chemical form of radioactivity appearing in peripheral blood and bile was assessed. 7-Ketolithocholic acid was extensively reduced in the liver to chenic acid and, to lesser extent, to ursodeoxycholic acid. Hepatic reduction was similar for both unconjugated as well as glycine- and taurine-conjugated 7-ketolithocholic acid. 7-Ketolithocholic acid was well absorbed. There was no biotransformation in the small intestinal lumen or during absorption, because all radioactivity recovered from the lumen or in peripheral blood was in unchanged 7-ketolithocholic acid. Biotransformation products in bile after jejunal infusion were similar to those after intravenous injection. The studies indicate that 7-ketolithocholic acid is likely to be a physiological precursor of ursodeoxycholic acid in healthy man.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7435569     DOI: 10.1152/ajpgi.1980.239.3.G161

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  18 in total

1.  Hepatic biotransformation and choleretic effect of 7-ketolithocholic acid in the rat.

Authors:  S Kanai; Y Sato; M Nokubo; K Kitani
Journal:  Lipids       Date:  1989-10       Impact factor: 1.880

Review 2.  Ursodeoxycholic acid in the treatment of liver diseases.

Authors:  S Saksena; R K Tandon
Journal:  Postgrad Med J       Date:  1997-02       Impact factor: 2.401

Review 3.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

Authors:  W H Bachrach; A F Hofmann
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

4.  In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment.

Authors:  G Rudolph; D N Gotthardt; P Kloeters-Plachky; H Kulaksiz; P Schirmacher; A Stiehl
Journal:  Dig Dis Sci       Date:  2011-06-09       Impact factor: 3.199

Review 5.  Clinical pharmacokinetics of therapeutic bile acids.

Authors:  A Crosignani; K D Setchell; P Invernizzi; A Larghi; C M Rodrigues; M Podda
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

6.  Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis.

Authors:  K D Setchell; C M Rodrigues; M Podda; A Crosignani
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

7.  [Relation between serum lipoprotein metabolism and biliary lipid metabolism].

Authors:  O Leiss; K von Bergmann
Journal:  Klin Wochenschr       Date:  1983-06-15

8.  Effect of bile acid feeding on hepatic steroid 12 alpha-hydroxylase activity in hamsters.

Authors:  S Kuroki; T Hoshita
Journal:  Lipids       Date:  1983-11       Impact factor: 1.880

9.  Value of serum determinations for prediction of increased ursodeoxycholic and chenodeoxycholic levels in bile.

Authors:  F Bazzoli; H Fromm; A Roda; A K Tunuguntla; E Roda; L Barbara; P Amin
Journal:  Dig Dis Sci       Date:  1985-07       Impact factor: 3.199

10.  Description and simulation of a physiological pharmacokinetic model for the metabolism and enterohepatic circulation of bile acids in man. Cholic acid in healthy man.

Authors:  A F Hofmann; G Molino; M Milanese; G Belforte
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.